Why is Boston Scientific stock plunging today?

Boston Scientific (BSX) stock fell 11.9% in pre-market trading after its Q3 2026 results. The company reported adjusted EPS of $0.73, missing estimates, and lowered its Q4 and full-year 2026 guidance due to a cyberattack and competitive pressures. Net sales grew 1.5% YoY to $5.14B, slightly beating expectations. The stock neared its 52-week low.

Original reporting
Published Oct 28, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance reduction and margin decline are likely to keep the stock under pressure, especially given the 11.9% pre‑market drop.

02

Market read

The earnings miss and guidance cut triggered a sharp sell‑off, making the news highly relevant for short‑term traders.

03

What to watch

Potential cost‑saving measures or insurance recoveries from the cyber incident are not yet quantified.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Boston Scientific disclosed Q3 results with modest revenue beat but missed EPS expectations and cut guidance, attributing the slowdown to a recent cyberattack and competitive pressure.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific reported Q3 earnings miss and cut full-year guidance, causing an 11.9% pre‑market plunge.

Expected impact

likely further decline as investors price in lower EPS forecasts and cyberattack fallout

Evidence & confidence

The earnings miss, sharp margin contraction, and reduced EPS outlook are fresh, material facts that moved the stock sharply.

Market effects

Medical device sector may see broader pressure as competitors gain share while Boston Scientific grapples with cyber‑attack disruptions.

U.S. equities could open lower, especially health‑care stocks, following the sharp move in BSX.

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

If the cyberattack impact is overstated, the stock could rebound on a short‑cover rally.

Key entities

  • Boston Scientific

    Medical device maker reporting Q3 2026 earnings.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.